Quantcast

Latest Angina pectoris Stories

2011-07-08 13:47:59

An injection of stem cells into the heart could offer hope to many of the 850,000 Americans whose chest pain doesn't subside even with medicine, angioplasty or surgery, according to a study in Circulation Research: Journal of the American Heart Association. Patients who received the new treatment reported half as many chest pain episodes and improved exercise capability compared to those who received a placebo. The study was the first randomized, controlled trial of stem-cell therapy to show...

2011-07-05 13:51:04

The greater the satisfaction, the greater the protection While depression and anxiety have long been recognised as risk factors for heart disease, there is less certainty over the beneficial effects of a 'positive' psychological state. Now, following a study of almost 8000 British civil servants, researchers say that a satisfying life is indeed good for the heart. The results of the study are published online today by the European Heart Journal. The civil servants - who were all members of...

2011-06-29 07:00:00

DURHAM, N.C., June 29, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent Drug-Eluting Coronary Stent System ("MiStent DES"), an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Based on results observed in the DESSOLVE I trial, Micell has reduced the sample size in its DESSOLVE...

2011-06-15 08:00:00

SAN DIEGO, June 15, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has received clearance from the Russian Ministry of Health and Social Development to commence a Phase 3 registration study for the Company's Generx(TM) (alferminogene tadenovec, Ad5FGF-4) biologic product candidate. Generx is a new and innovative DNA-based angiogenic therapy designed for the potential treatment of myocardial ischemia due to coronary artery disease. The Russian Health...

2011-05-18 08:00:00

-- Presentation at Leading European Cardiovascular Conference Highlights Positive Data to Date for Patient Treated during TCT Live Case -- VANCOUVER, BC, and PARIS, France, May 18 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today reported positive six-month follow-up data for a patient with severe refractory angina who received the Neovasc Reducer(TM) product in a "live case" procedure broadcast during the 22nd annual...

2011-05-11 07:00:00

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that positive preclinical data will be presented at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled, "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities." The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing...

2011-04-04 17:05:59

Ranolazine (Ranexa, Gilead) is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3. Patients with refractory angina, who have chronic chest pain but are not candidates for revascularization, have limited therapeutic options and significant limitations in their...

2011-03-18 00:00:26

Indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease Cranford, NJ (PRWEB) March 16, 2011 Coronary artery disease (CAD), also known as coronary heart disease, is the most common type of heart disease, currently affecting about 17 million Americans.(1) Most of these people suffer from a common symptom of CAD known as angina pectoris. For over 100 years, physicians have treated acute angina with nitrates, the most common form being...

2011-03-16 02:00:00

CRANFORD, N.J., March 16, 2011 /PRNewswire/ -- Coronary artery disease (CAD), also known as coronary heart disease, is the most common type of heart disease, currently affecting about 17 million Americans(1). Most of these people suffer from a common symptom of CAD known as angina pectoris. For over 100 years, physicians have treated acute angina with nitrates, the most common form being nitroglycerin(2). Considered the gold standard in treating acute angina, nitroglycerin tablets have...

2011-02-25 12:22:52

Successful initiation of trial for new device designed to treat patients who suffer from refractory angina The interventional cardiology team at the Montreal Heart Institute (MHI) recently began patient enrolment for a new device, the Neovasc ReducerTM, designed to treat patients suffering from refractory angina. The treatment method is a first in North America and is being conducted as part of an international study, the COSIRA trial. This innovative treatment is promising for thousands of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'